FDA’s Suggested Acetaminophen Allergy Warning Tracks Industry Change
This article was originally published in The Tan Sheet
Executive Summary
The recommendation in a draft guidance covering single- and combination-ingredient acetaminophen products marketed under the tentative final monograph for internal analgesics mirrors a warning that some OTC manufacturers already are using on their products.
You may also be interested in...
In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor
Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.
In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor
Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.
Draft Guidance Drills Down With Details To Cut Pediatric Acetaminophen Overdose Risk
FDA suggests new and repeats previous recommendations to reduce the risk of pediatric overdose with acetaminophen products due either to unsupervised ingestion or therapeutic errors. The guidance includes greater detail on delivery devices and labeling information for pediatric acetaminophen OTCs.